Vandœuvre-lès-Nancy, April 16th 2020,
In the current pandemic context, PAT announces the initiation of preliminary tests against the SARS-CoV-2 virus (Covid-19) for two of its active ingredients presently under development.
These active ingredients, which come from the company’s exclusive portfolio and which production is already under control and protected by patents, have demonstrated in vitro and in vivo an ability to regulate general inflammation as well as an in vitro antiviral capacity on respiratory viruses like bronchiolitis (RSV) and influenza (H1N1) type.
In the event of positive results on SARS-CoV-2, the positioning of these products would be truly original because their dual antiviral and anti-inflammatory action could address both the viral load and the exaggerated inflammation responsible for pulmonary dysfunctions observed in patients with severe forms.
The development of these products could be accelerated in the current context but will nevertheless require rigorous monitoring of the protocols in order to be able, in the long term, to end up with new treatments to the benefit of patients suffering from the virus.